BACKGROUND
Using a synthetic biology approach, Eukarÿs has developed C3P3, an unprecedented eukaryotic artificial expression system. C3P3 is based on the use of an artificial RNA polymerase, which produces mature eukaryotic mRNA. The system is currently in its fourth generation. Progressive improvements in its performance enabled the use of C3P3 first for the development of bioproduction tools and thereafter for vaccines.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Eukarÿs’s bioproduction tools can currently be used transiently with very good yields. The system is currently used by many academic molecular-virology laboratories and by pharmaceutical companies for the production of wild-type and recombinant viruses. These tools are available under a license agreement. Eukarÿs intends to launch the development of a stable, recombinant-protein production system in 2023.
The company’s synthetic gene vaccine platform is based on the administration of synthetic DNA coding for both the C3P3 enzyme and the gene(s) of interest. This synthetic DNA is produced using Eukarÿs’s proprietary technology. Synthetic DNA enables self-amplification of antigen expression by means of multiple amplification loops, which increase its efficiency. This vaccine system is in the non-regulatory clinical phase, but also in the development phase for its therapeutic immuno-oncological use in primary liver cancer.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
Improved performance of the C3P3 system now in its fourth generation.
Development of tools for the bioproduction of recombinant viruses. Agreement with a major actor in the pharmaceutical industry (confidential).
Development of an auto-amplification technology used for synthetic gene vaccination.
Ongoing optimization of the synthetic DNA production technology used for vaccinal purposes.
COLLABORATIONS SOUGHT
License agreements or partnerships for the use of Eukarÿs’s tools for the bioproduction of wild-type viruses, recombinant viruses or recombinant proteins.
Licensing agreements or partnerships for the development of synthetic gene vaccines and immuno-oncology therapeutics.
